Axsome Therapeutics (NASDAQ: AXSM) has done something most other stocks haven't been able to do this year: It's beaten the bear market. The shares are heading for a 111% gain as the S&P 500 heads for a 16% loss.

Axsome's performance isn't random -- there's a clear reason for it. This dynamic biotech company commercialized its first two products and is moving closer to possibly launching others in the next few years.

All of that sounds great. But you might be wondering if there's any share-performance potential left. After such gains, is Axsome still worth buying before 2023? Let's find out.

Continue reading

Source Fool.com